CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

Lancet Oncology

Volumn 7, Issue 5, 2006, Pages 379-391

  Pfreundschuh, Michael ^a   Trümper, Lorenz ^b   Österborg, Anders ^c   Pettengell, Ruth ^d   Trneny, Marek ^e   Imrie, Kevin ^f   Ma, David ^g   Gill, Devinder ^h   Walewski, Jan ⁱ   Zinzani, Pier Luigi ^j   Stahel, Rolf ^k   Kvaloy, Stein ^l   Shpilberg, Ofer ^m   Jaeger, Ulrich ⁿ   Hansen, Mads ^o   Lehtinen, Tuula ^p   López Guillermo, Armando ^q   Corrado, Claudia ^r   Scheliga, Adriana ^s   Milpied, Noel ^t   Mendila, Myriam ^u   Rashford, Michelle ^u   Kuhnt, Evelyn ^v   Loeffler, Markus ^w   more..

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e CHARLES UNIVERSITY   (Czech Republic)

^f DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^g ST VINCENT S HOSPITAL   (Australia)

^h PRINCESS ALEXANDRA HOSPITAL   (Australia)

ⁱ INSTITUTE OF ONCOLOGY   (Poland)

^j Institute of Haematology   (Italy)

^k UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^l Radium Hospital   (Norway)

^m BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

ⁿ UNIVERSITY OF VIENNA   (Austria)

^o Rigshospitalet   (Denmark)

^p Pikonlinnan sairaala   (Finland)

^q H Clinic i Provincial   (Spain)

^r Fundacion para Combatir La Leucemia   (Argentina)

^s INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^t NANTES UNIVERSITY HOSPITAL   (France)

^u F HOFFMANN LA ROCHE LTD   (Switzerland)

^v Coordinating Centre for Clinical Trials ^*  (Germany)

^w UNIVERSITY OF LEIPZIG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; MITOXANTRONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANEMIA; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; DRUG RESPONSE; FEMALE; FOLLOW UP; FREQUENCY ANALYSIS; HEART INFARCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION; LARGE CELL LYMPHOMA; LEUKOPENIA; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SECOND CANCER; SEPSIS; SEPTICEMIA; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, DIFFUSE; MIDDLE AGED; PREDNISONE; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE;

EID: 33646004738     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(06)70664-7     Document Type: Article

References (16)

1. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329 (1993) 987-994
2. Miller T., Dahlberg S., Cassady J., et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 339 (1998) 21-26
3. Pfreundschuh M., Trumper L., Kloess M., et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104 (2004) 626-633
4. Reyes F., Lepage E., Ganem G., et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 352 (2005) 1197-1205
5. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 235-242
6. Feugier P., Van Hoof A., Sebban C., et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23 (2005) 4117-4126
7. Habermann T., Weller E., Cassileth P., et al. Phase III trial of rituximab-CHOP (R-CHOP) vs CHOP with a second randomization to maintenance rituximab or observation in patients 60 years of age and older with diffuse large B-cell lymphoma. Blood 102 (2003) 103 (abstr)
8. Harris N., Jaffe E., Diebold J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17 (1999) 3835-3849
9. Lister T., Crowther D., Sutcliffe S., et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7 (1989) 1630-1636
10. Cheson B., Horning S., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17 (1999) 1244
11. Pfreundschuh M., Klöss M., Schmits R., et al. Six, not eight cycles of bi-weekly CHOP with rituximab (R-CHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): results of the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 106 (2005) 9 (abstr)
12. Miller T., Unger J., Spier C., et al. Effect of adding rituximab to three cycles of CHOP plus inolved-field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG-0014). Blood 104 (2004) 48 (abstr)
13. Fisher R., Gaynor E., Dahlberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328 (1993) 1002-1006
14. Sehn L., Donaldson J., Chhanabhai M., et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23 (2005) 5027-5033
15. Glass B., Kloess M., Engert A., et al. Dose esclated CHOP + etoposide and repetitive autologous stem cell transplantation (MegaCHOEP) with and without rituximab for primary treatment of aggressive NHL. J Clin Oncol 23 suppl (2005) 598S
16. Pfreundschuh M., Trumper L., Kloess M., et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104 (2004) 634-641